| Literature DB >> 26080612 |
B J Boyarsky1, C M Durand2, F J Palella3, D L Segev1,4.
Abstract
Life expectancy among HIV-infected (HIV+) individuals has improved dramatically with effective antiretroviral therapy. Consequently, chronic diseases such as end-stage liver and kidney disease are growing causes of morbidity and mortality. HIV+ individuals can have excellent outcomes after solid organ transplantation, and the need for transplantation in this population is increasing. However, there is a significant organ shortage, and HIV+ individuals experience higher mortality rates on transplant waitlists. In South Africa, the use of organs from HIV+ deceased donors (HIVDD) has been successful, but until recently federal law prohibited this practice in the United States. With the recognition that organs from HIVDD could fill a critical need, the HIV Organ Policy Equity (HOPE) Act was passed in November 2013, reversing the federal ban on the use of HIV+ donors for HIV+ recipients. In translating this policy into practice, the biologic risks of using HIV+ donors need to be carefully considered. In this mini-review, we explore relevant aspects of HIV virology, antiretroviral treatment, drug resistance, opportunistic infections and HIV-related organ dysfunction that are critical to a transplant team considering HIV-to-HIV transplantation. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: Infection and infectious agents; kidney failure/injury; liver (native) function/dysfunction; viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
Mesh:
Substances:
Year: 2015 PMID: 26080612 DOI: 10.1111/ajt.13344
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086